The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
A novel, non-invasive treatment using electrical currents exploits physiological properties of dividing cancer cells to prolong survival and augment current therapies.
A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
In this webinar, Dr. Kevin Wang will discuss a precision medicine approach for treating traumatic brain injury which uses phenotype biomarkers to monitor disease course and develop novel therapies.
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Researchers overseeing the clinical trial for the first FDA-approved oral contraceptive claimed the drug gave the Puerto Rican participants power over their family planning. Critics claimed the women were exploited.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.
The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.
A review by the US Office of Inspector General found that only about half of the scientists running clinical trials funded by the NIH in 2019 and 2020 appropriately recorded their findings in a federal database, as is legally required.
At Brigham and Women’s Hospital, the cancer biologist is combining research into the tumor microenvironment with the principles of neuroscience to tease apart how cancers grow—and how to stop them.